More Related Content
Similar to personelize medicine.pptx (20)
More from phindomawardinata (8)
Recently uploaded (20)
personelize medicine.pptx
- 2. Personalised Cancer Medicine Flashcards 2022 Ovarian Cancer Breast Cancer Colorectal Cancer Gastric Cancer Lung Cancer Prostate Cancer Pancreatic Cancer GIST
- 3. 1. Garrido P, Conde E, de Castro J, et al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020 Jul;22(7):989-1003. doi: 10.1007/s12094-019-02218-4. . 2. Colomer R, Mondejar R, Romero-Laorden N et al,. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487.. 3. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014.. 4. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006A.pdf EGFR ALK ROS1 PDL-1 RET NTRK* KRAS y MET* BRAF V600 NGS** HER2 NRG1 **in biopsies with little sample; Approved in the USA as accompanying diagnosis of EGFR and ALK inhibitors *in tumors lacking driver mutations Personalised Cancer Medicine Flashcards 2022 Lung Cancer The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA
- 4. 1. Colomer R, Aranda-L坦pez I, Albanell J, Garc鱈a-Caballero T, Ciruelos E, L坦pez-Garc鱈a M, Cort辿s J, Rojo F, Mart鱈n M, Palacios-Calvo J. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018 Jul;20(7):815-826. doi: 10.1007/s12094-017-1800-5. 2. Litton JK, Burstein HJ, Turner NC. Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e1-e7. doi: 10.1200/EDBK_237715. 3. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006A.pdf Estrogen Receptor Progesterone Receptor HER2 NGS Genetic platforms: Mammaprint, Oncotype, Prosigna, or Endopredict* BRCA 1 and BRCA 2** PDL-1*** PIK3CA**** ESR1 FGFR1 AKT1 PTEN Liquid biopsy and circulating cancer cells Approved in US as companion diagnostics of a PI3K inhibitor *in early luminal breast cancer with high risk of relapsing **in advanced triple negative or luminal breast cancer *** in advanced triple negative breast cancer **** in advanced luminal breast cancer Personalised Cancer Medicine Flashcards 2022 Breast Cancer The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA
- 5. 1. Garc鱈a-Alfonso P, Garc鱈a-Carbonero R, Garc鱈a-Foncillas J, et al. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2020 Nov;22(11):1976-1991. doi: 10.1007/s12094-020-02357-z. 2. Kolen鱈k D, Shishido SN, Pitule P, et al. Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges. Cancers (Basel). 2020 May 27;12(6):1376. doi: 10.3390/cancers12061376. 3. Garrido P, Hladun R, de lava E, et al. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. Clin Transl Oncol. 2021 Feb 23. doi: 10.1007/s12094-021- 02558-0 Microsatellite Instability study* KRAS, NRAS BRAF DPD Inmunoscore CMS classification MET EGFR FGFR PI3K ** in tumors with microsatellite instability, MIG1 hypermetilation and RAS wild type (IHQ + FISH, NGS, RT-PCR, NanoString) ***(IHC or FISH or NGS) en RAS y BRAF WT * by IHC (MLH1, PMS2, MSH2 and MSH6) or genetic study (BAT25 and BAT26, D2S123, D5S346 and D17S250). Personalised Cancer Medicine Flashcards 2022 Colorectal Cancer The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA NTRK** HER2***
- 6. 1. G坦mez-Mart鱈n C, Concha A, Corominas JM, et al; Spanish Society of Medical Oncology; Spanish Society of Pathology. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol. 2011 Sep;13(9):636-51. doi: 10.1007/s12094-011-0709-7. 2. Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi: 10.1001/jamaoncol.2020.3370. Microsatellite Instability* PDL-1 VEGFR EGFR MET EBV Personalised Cancer Medicine Flashcards 2022 Gastric Cancer *by either IHQ (MLH1, PMS2, MSH2 and MSH6) or by Genomic studies (BAT25 and BAT26, D2S123, D5S346 and D17S250). The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA HER2
- 7. 1. Mart鱈n-Algarra S, Fern叩ndez-Figueras MT, L坦pez-Mart鱈n JA, at al; Spanish Society of Pathology; Spanish Society of Medical Oncology. Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014 Apr;16(4):362-73. doi: 10.1007/s12094- 013-1090-5. 2. Scherrer E, Rau R, Lorenzi M, Shui I, Townson S, Larkin J. Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. Future Oncol. 2021 Mar 30. doi: 10.2217/fon-2021-0154.. 3. Mao L, Dai J, Cao Y, et al. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021 Mar 23;148:297-306. doi: 10.1016/j.ejca.2021.02.021. Tumor mutational burden NRAS GNAQ/GNA11 PTEN MITF CDKN2A MHC-II KIT* Personalised Cancer Medicine Flashcards 2022 Melanoma *in mucosal or acral melanoma or melanoma associated with sunlight The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA BRAF
- 8. BRCA1 and BRCA2* Homologous Recombination Deficiency (HRD) NGS** p53, PD-1/PDL-1, ATM, BARD1, BRIP1, CHECK1, CHECK2, FAM175A, MRE11A, NBN, PALB2, RAD51C, RAR51D. **approved in US as companion diagnostics for some PAPR inhibitors *germ-line or somatic Personalised Cancer Medicine Flashcards 2022 Ovarian Cancer 1. Oaknin A, Guarch R, Barretina P, et al. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA
- 9. BRCA1 and BRCA2* Microsatellite instability* HRR Profound panel * (somatic) * By either IHC (MLH1, PMS2, MSH2 a MSH6) or by genomic study(BAT25 and BAT26, D2S123, D5S346 and D17S250). *germ-line or somatic Personalised Cancer Medicine Flashcards 2022 Prostate Cancer 1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. 2. 2. To SQ, Kwan EM, Fettke HC, et al. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Jun;73(6):818-821. doi: 10.1016/j.eururo.2018.01.007. 3. 3. Beltran H, Antonarakis ES, Morris MJ, Attard G. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. Am Soc Clin Oncol Educ Book. 2016;35:131-41. doi: 10.1200/EDBK_159248. The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA Androgen receptor aberrations PDL1 PTEN
- 10. 1. Curtin NJ, Drew Y, Sharma-Saha S. Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nat Rev Clin Oncol. 2019 Dec;16(12):725-726. doi: 10.1038/s41571-019-0285-2. 2. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. 3. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317- 327. doi: 10.1056/NEJMoa1903387. Germ-line BRCA 1-2 Microsatellite Instability* ATM, PALB2, p53, KRAS, CDKN2, SMAD4, MLL3, TGFBR2, ARID1A, ALK, BRAF, HER2, ROS, RRG1 Personalised Cancer Medicine Flashcards 2022 Pancreatic Cancer * By either IHC (MLH1, PMS2, MSH2 a MSH6) or by genomic study(BAT25 and BAT26, D2S123, D5S346 and D17S250). The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA NTRK
- 11. 1. Martin-Broto J, Martinez-Mar鱈n V, Serrano et al. Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. Clin Transl Oncol. 2017 May;19(5):536-545. doi: 10.1007/s12094-016-1581-2. CD 117/c-kit CD34 Number of mitosis/50 large fields KIT and PDGFR mutations NF1 RAS FGFR DOG1* BRAF, SDHB, NTRK** ** GIST wild type * CD117 negative Personalised Cancer Medicine Flashcards 2022 GIST The Standard category is based on current treatment indications with approved funding by the Spanish National Health System The Recommended category is based on current recommendations by EMEA and FDA
- 12. Personalised Cancer Medicine Flashcards 2022 February 2022
Editor's Notes
- #9: Receptor de folato? En currently not recommended